T he results of total knee replacement (TKR) are commonly assessed by survival analysis using revision as the endpoint. We have used the assessment of pain by a patient-based questionnaire as an alternative.
Survival analysis is commonly used for assessment of outcome after total knee replacement (TKR) since data from patients with different lengths of follow-up can be used. 1 With survival analysis a single outcome is chosen, which is usually revision. There are, however, problems using revision and it is often unrelated to the design of the TKR. Revision is relatively uncommon after modern TKRs and inaccuracies may arise from loss to follow-up and the small numbers involved. 2 In many studies, more patients are lost to follow-up than are revised, and therefore survival analysis may give a falsely optimistic assessment of the outcome. 3 The low rates of revision make it difficult to distinguish between different types of TKR. Endpoints which are more common than revision would be more valuable in survival analysis. 2 Many different factors can be assessed after joint replacement including pain, range of movement, walking and the radiological appearance. In a recent review of THR, pain was found to be the best single outcome measure, in that it had the highest correlation with patient satisfaction and subsequent revision, and could be used as an endpoint in survival analysis. 4, 5 Pain is usually assessed by the surgeon or one of his assistants, but many patients do not give a full account of their symptoms in these circumstances and this gives an overoptimistic result. 6 It is better to use the patient's own evaluation of pain. We compared the use of revision as an endpoint with the development of different levels of pain as assessed on a patient-completed questionnaire for survival analysis.
Patients and Methods
We assessed all patients having TKR in our institution between 1987 and 1993. The mean follow-up was 3.5 years (1 to 8). There were 1429 arthroplasties carried out by 66 surgeons; 1162 received the AGC (Biomet Ltd, Swindon, UK), 163 the IB2 (Zimmer, Swindon, UK) and 104 the Nuffield Knee (Corin Medical, Cirencester, UK).
Patients were assessed retrospectively after TKR by a postal questionnaire. First, their general practitioners (GP) were contacted to determine if they had died or would be unable to complete the questionnaire. In these circumstances information about reoperation was obtained from the GP and the hospital records. Questionnaires were sent to all other patients to determine whether any further knee operations had been undertaken and also the level of pain (none, mild, moderate or severe) experienced before operation and in each year subsequently. If the questionnaires were not returned a second questionnaire was sent and, if necessary, the patients were telephoned. Further information was obtained from the notes and radiographs.
Survival analyses, using the life-table method, 2 were undertaken with four different endpoints: revision, severe pain or revision, moderate or severe pain or revision, and mild, moderate or severe pain or revision. 5 The time to reach the various endpoints was determined for each patient. If, after operation, they had pain which had improved by the second year, the initial pain was ignored. When revision was the endpoint all patients were included in the analysis. When the endpoint included pain, only the patients who had completed questionnaires were included. The method described by Peto et al 7 was used to calculate 95% confidence intervals. The log-rank test was used for comparisons in which data from the full length of followup were used.
Results
Only 62 patients were lost to follow-up so that in 96% of patients it was known whether the TKR had been revised or not. In 97% of the patients who were alive and fit enough to be sent a questionnaire the levels of pain were known. The AGC and Nuffield Knee had similar groups of patients whereas there were more cases of rheumatoid arthritis in those with the IB2 (Table I) . As shown in Figure 1 , with revision as the endpoint, the cumulative survival rate at seven years was 97.5% (94 to 100). When a worst-case curve was generated by assuming that all patients lost to follow-up were failures, 2 the survival rate at seven years was 83.8% (77 to 91). The reasons for revision are given in Table II . It was found that the rate of revision was not affected significantly by a diagnosis of osteoarthritis or rheumatoid arthritis (p = 0.688), patient age below or above 60 years at operation (p = 0.855) or the grade of the surgeon (p = 0.991). As shown in Figure 2 there were no significant differences for survival between the three types of implant (p = 0.720). Between 6% and 13% of the patients also had arthroplasty of the patella at the time of knee replacement, and none of these prostheses has failed. Of those patients who did not have a resurfacing of the patella, between 1% and 6% subsequently required it. A survival analysis was therefore undertaken in which the endpoint was revision or subsequent patellar resurfacing. This gave a survival rate at seven years for the AGC of 94.3% (88 to 100). This was not significantly different from the IB2 (p = 0.59). The Nuffield Knee, however, had a significantly lower survival (p = 0.002) than the AGC with this endpoint (Fig. 3) Tables III and IV. Survival analysis was undertaken with the development of various levels of pain as the endpoints (Figs 4 to 6 ). There were no significant differences between the AGC and IB2 but both were significantly better than the Nuffield, with the difference most marked for moderate pain. The levels of significance were p = 0.036 for severe, p = 0.007 for moderate and p = 0.015 for mild pain. With the AGC and IB2 85.3% (78 to 92) of the patients had not developed severe pain by seven years, 71.7% (63 to 81) had not developed moderate pain and 39.1% (30 to 48) had not developed mild pain. At seven years the confidence intervals for the survival rate for the Nuffield Knee were very wide and therefore the figures at five years are more appropriate for a comparison. These were: using severe pain 89.1% (86 to 93) for the AGC and IB2, and 78.5% (65 to 92) for the Nuffield; using moderate pain 74.5% (70 to 79) for the AGC and IB2, and 55.5% (41 to 71) for the Nuffield; using mild pain 45.2% (40 to 51) for the AGC and IB2, and 25.3% (13 to 38) for the Nuffield.
As moderate pain appeared to be the most discriminating endpoint other variables were studied using this endpoint for patients having the AGC and IB2. It was found that neither age, diagnosis nor grade of surgeon (consultant or other) affected the outcome significantly (p = 0.7, p = 0.07, p = 0.5, respectively). The survival rates at five years were: 72.4% (61 to 84) for patients under 60 years and 74.7% (69 to 80) for those over 60 years; 73.2% (67 to 79) for Survival curves for the three types of implant with revision as the endpoint.
Fig. 3
Survival curves for the three types of implant with revision or subsequent patellar resurfacing as the endpoint. 
Discussion
In orthopaedic surgery, revision is usually used as the endpoint in survival analysis, but this failed to distinguish between the three types of TKR. All had survival rates of about 97% at seven years, which is similar to those in other published series. [8] [9] [10] This suggests that there is either no difference between the implants or that the technique used to distinguish between them is inadequate. With modern TKR the revision rates are so low that traditional methods of survival analysis, using revision as the endpoint, are unlikely to be useful for comparisons unless there are very large numbers of patients. Even then, differences may not be related to implant design. Survival analysis using various levels of pain, particularly moderate pain, as endpoints appears to be a much more satisfactory method of comparing implants. Many fewer patients are needed to demonstrate significant differences.
Joint replacement is undertaken primarily for pain and relief of this is likely to be the most important long-term outcome for a patient. The level of pain correlates with patient satisfaction and predicts the need for subsequent revision. 4 Pain must be assessed by the patients themselves since they do not always inform their surgeons about their symptoms. 6 Ideally, pain should be assessed prospectively since retrospective review may introduce bias. Our study was retrospective and therefore the proportion of patients who developed pain may be inaccurate. Since all patients were assessed in an identical manner, however, comparisons made within the trial are likely to be valid. In our study, similar groups of patients received the AGC and the Nuffield Knee. More patients with rheumatoid arthritis had the IB2 than the AGC or Nuffield, but the diagnosis did not significantly influence the outcome. The AGC and IB2 appear to have given similar results, which are better than the Nuffield Knee. This may have been due to the patellofemoral joint as more patients needed subsequent resurfacing of the patella with the Nuffield Knee than with the AGC or IB2, but there are other important design differences between the implants.
We found that by seven years 30% of patients had developed moderate pain. One possible reason for the high proportion of patients with pain is that the patella had not been resurfaced routinely. We believe that this is not the case as there have been a number of randomised, doubleblind, controlled trials and trials in bilateral knees which have investigated whether routine resurfacing of the patella is an advantage, [11] [12] [13] [14] which have not reached a clear conclusion.
The IB2 and the AGC are the TKRs which have given the best results at ten years. 8, 10, 15, 16 Despite this we found that the failure rate, using moderate pain as the endpoint, was about 30% at seven years. This does not necessarily mean that at seven years 30% of patients had moderate pain or worse; indeed only 17% were in this category (Fig. 7) . It indicates that by seven years 30% have had moderate pain at some time after their initial recovery. This method provides a more sensitive assessment of pain after TKR and indicates that, even with the best available implants, a substantial proportion of patients has significant symptoms even although their arthroplasty has not been revised. It is essential that we determine why this pain occurs so that further improvements can be made in design and technique.
Such modifications can then be tested using the more sensitive measures which we have described.
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